Biotechnology

Monday Feb 01, 2021 - 3:23 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, president and CEO of Genprex. “The primary focus this past…

Monday Feb 01, 2021 - 12:30 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Med-Tech Innovation Article

Brain Scientific (OTCQB: BRSF), a neurology focused device and software company, was featured in a recent Med-Tech Innovation article titled, “The need for neurological disposable tech amid the COVID-19 pandemic.” In the piece, Brain Scientific’s VP of Marketing, Stuart Bernstein, examines the need of neurological disposable technology following the effects of COVID0-19. “The solution is clear and has come in the form of disposable EEG…

Friday Jan 29, 2021 - 3:09 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Across Continuum of Health Care

United Medical Equipment (“UME,” “UMEBSNI”) continues to address unique testing needs created by the ongoing global pandemic. As part of the company’s efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits that detect coronavirus antibodies that appear in the bloodstream of infected individuals within 10 minutes. The test can also indicate whether a person…

Friday Jan 29, 2021 - 2:40 pm

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Promising Results from CyberAgrot Study

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, recently released potentially industry-changing results for its initial Colombia laboratory test. The study evaluated the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto…

Thursday Jan 28, 2021 - 2:04 pm

InvestorNewsBreaks – Clearside Biomedical Inc. (NASDAQ: CLSD) Closes Sale of Common Stock for $12M

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that it has closed the sale of 4,209,050 shares of common stock. The shares were priced at $2.851 per share, with the sale resulting in approximately $12 million. In the announcement, Clearside noted that the sale took…

Thursday Jan 28, 2021 - 1:02 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Featured in BioWorld MedTech Article

Brain Scientific (OTCQB: BRSF), a neurology focused device and software company, was featured in a recent BioWorld MedTech article titled, “Brain Scientific begins development of E-Tattoo device for continuous brain monitoring.” The piece covers Brain Scientific’s efforts to combine a miniaturized electroencephalogram (“EEG”) with subcutaneous graphene electrodes to produce a minimally invasive brain monitoring device that could provide continuous data on patients with neurological conditions.…

Thursday Jan 28, 2021 - 12:10 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Strategic Contract with Large Pharmaceutical Company

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced a contract between its wholly owned subsidiary, Soluble Biotech Inc., with a large pharmaceutical company. According to the update, the work will involve using Soluble Biotech’s proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical…

Thursday Jan 28, 2021 - 10:54 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Drug Formulation Strategy, 2021 Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its drug formulation and delivery business strategy and milestones for 2021. According to the update, XPhyto, as a bioscience accelerator at the leading-edge of the life science industry, targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. Regarding XPhyto's drug formulation business,…

Thursday Jan 28, 2021 - 10:41 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION…

Wednesday Jan 27, 2021 - 3:12 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health…

Wednesday Jan 27, 2021 - 1:32 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and…

Wednesday Jan 27, 2021 - 12:18 pm

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for…

Tuesday Jan 26, 2021 - 11:37 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Addition of Two Clinical Trial Sites for MS1819 Phase 2b OPTION 2 Extension Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has added two clinical trial sites for the extension arm of its MS1819 Phase 2b OPTION 2 study. The study is investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). The additional sites were added in Poland; Europe was selected to reduce…

Friday Jan 22, 2021 - 12:50 pm

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000…

Thursday Jan 21, 2021 - 11:40 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Announces Plans to Develop Micro Brain E-Tattoo Device for Growing Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has begun development of a brain E-Tattoo device. The company announced that the innovative product will feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The electrodes will connect to the micro EEG, which will be located behind the ear and which processes signals from the sensors and…

Thursday Jan 21, 2021 - 11:00 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is…

Thursday Jan 21, 2021 - 10:29 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light on recent advancements concerning its upcoming clinical trials for the…

Wednesday Jan 20, 2021 - 10:47 am

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Lab Test Results of Patented Biopesticide Achieve 100% Control of Root-Rot Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced successful test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores ("Aphanomyces"). The tests, conducted via an independent third-party facility, achieved 100% control of the root-rot disease Aphanomyces zoospores at economic application rates within 24 hours; Aphanomyces is a soil-borne disease that destroys…

Wednesday Jan 20, 2021 - 10:46 am

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Collaboration to Evaluate Feasibility of Ultra Shear Technology Platform to Improve Effectiveness of SinuSys Lead Product Candidate

Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI's innovative Ultra Shear Technology(TM) ("UST") platform to strengthen the effectiveness of SinuSys Corp's lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI's UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later…

Wednesday Jan 20, 2021 - 10:23 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital") to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange ("CSE").…

Wednesday Jan 20, 2021 - 9:38 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategy for New Year; Outlines Expected Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released its business strategy and expected milestones for 2021. The company noted that in the coming year it anticipates commercialization of its proprietary rapid COVID-19 PCR (“PCR”) test as well as clinical validation of is exclusive transdermal and sublingual drug formulations; XPhyto is also planning on…

Wednesday Jan 20, 2021 - 9:14 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Executive Chairman Quoted in Elite Healthcare Article Noting How the Pandemic Might Impact Healthcare in 2021

Brain Scientific (OTCQB: BRSF) co-founder and executive chairman Boris Goldstein was quoted in a recent Elite Healthcare article titled “A Look at 2021 Healthcare with the Pandemic.” The article quoted a variety of clinicians and industry professionals who consider themselves futurists and who specialize in exploring predictions and possibilities based on present trends. The article discussed health care in 2021 from a variety of standpoints including…

Tuesday Jan 19, 2021 - 11:13 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common…

Tuesday Jan 19, 2021 - 10:33 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Verifies Active Ingredient in Biopesticide Offering Positively Impacts Soil Health

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, this morning reported that third party studies have confirmed that Allyl Isothiocyanate ("AITC"), the active ingredient in MustGrow's mustard plant-based technology, has a positive impact on soil health, contributing to the environmental and ecological security of plant-based food supply and the planet. The company’s…

Friday Jan 15, 2021 - 9:48 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Pharma Mirror Magazine Article

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in a recent article published by Pharma Mirror Magazine. The article titled, “Neurology’s Growing Need for Disposable Technologies,” is written by Brain Scientific’s co-founder and executive chairman. The piece indicates that several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. “When conditions like…

Thursday Jan 14, 2021 - 1:00 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of…

Thursday Jan 14, 2021 - 11:58 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced…

Thursday Jan 14, 2021 - 11:19 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Confirms Proceeds of C$1.5M from Warrant Exercise

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced its receipt of over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share. The company intends to use the proceeds of the warrant exercise to advance its organic…

Wednesday Jan 13, 2021 - 11:27 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This achievement comes in advance of GNPX’s upcoming Acclaim-1 and Acclaim-2…

Wednesday Jan 13, 2021 - 11:24 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Initiates Program to Identify UK, South African COVID Sequences

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started…

Wednesday Jan 13, 2021 - 11:02 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets,…

Wednesday Jan 13, 2021 - 10:32 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario's…

Wednesday Jan 13, 2021 - 9:46 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA…

Tuesday Jan 12, 2021 - 12:57 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient…

Tuesday Jan 12, 2021 - 11:47 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers use of niclosamide as a treatment for COVID-19-associated GI disease.…

Monday Jan 11, 2021 - 1:23 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In addition, the press release can also be viewed on the…

Monday Jan 11, 2021 - 12:10 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Biotech Showcase(TM) Digital 2021 Conference. According to the update, the conference is taking place online between January 11-15 and will feature prerecorded sessions of…

Friday Jan 08, 2021 - 12:22 pm

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) COO Shines the Spotlight on Proprietary Tech, Unique Value Proposition

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, was featured in a recent SmallCap-Investor interview. The company’s COO Colin Bletsky joined the interview to discuss MustGrow and its unique value proposition and ambitious plans for the future. Bletsky explained that a rigorous scientific process stands behind MustGrow’s proprietary technology, in which…

Friday Jan 08, 2021 - 12:19 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock at a purchase price of $0.842 per share. The company expects to secure gross proceeds of…

Friday Jan 08, 2021 - 11:56 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions